Synthesis and antitumor activity of aromatic camptothecin esters

International Journal of Molecular Medicine

Volumn 21, Issue 4, 2008, Pages 477-487

  Cao, Zhisong ^a   Mendoza, John ^a   Dejesus, Albert ^a   Vardeman, Dana ^a   Giovanella, Beppino ^a  

^a Stehlin Found for Cancer Research   (United States)

Author keywords

Alkaloids; Camptothecin; Chemical synthesis; Structure activity relationship

Indexed keywords

9 NITROCAMPTOTHECIN 20 O 1,2 BROMOBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,2 CHLOROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,2 FLUOROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,2 HYDROXYLBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,2 NITROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,3 BROMOBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,3 CHLOROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,3 CYANOBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,3 FLUOROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,3 NITROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,4 CHLOROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,4 CYANOBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,4 DINITROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,4 FLUOROBENZOATE; 9 NITROCAMPTOTHECIN 20 O 1,4 NITROBENZOATE; 9 NITROCAMPTOTHECIN 20 O BENZOATE; AROMATIC CARBOXYLIC ACID; CAMPTOTHECIN; CAMPTOTHECIN 20 O 1,3 NITROBENZOATE; CAMPTOTHECIN 20 O 1,3 TRIFLUOROMETHYLBENZOATE; CAMPTOTHECIN 20 O 1,4 DINITROBENZOATE; CAMPTOTHECIN 20 O 1,4 NITROBENZOATE; CAMPTOTHECIN 20 O 1,4 TRIFLUOROMETHYLBENZOATE; CAMPTOTHECIN 20 O 3,3 DINITROBENZOATE; CAMPTOTHECIN 20 O BENZOATE; CAMPTOTHECIN DERIVATIVE; ESTER DERIVATIVE; HALOGEN; RUBITECAN; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ACYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; QUANTUM YIELD; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG SCREENING; ESTERIFICATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERIFICATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44649101382     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.21.4.477     Document Type: Article

References (30)

1. Wall ME, Wani MC, Cook CE, Palmer K, McPhail AT and Sim GA: Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
2. Gottlieb JA, Guarino AM, Call JB, Oliverio VT and Block JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461-470, 1970.
3. Gottlieb JA and Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103-105, 1972.
4. Muggia FM, Creaven PJ, Hansen HH, Cohen MH and Selawry OS: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
5. Moertel CG, Schutt AJ, Reitemeier RJ and Hahn RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972.
6. Schaeppi U, Fleishman RW and Cooney DA: Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep 58: 25-36, 1974.
7. Wani MC, Ronman PE, Lindley LT and Wall ME: Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs. J Med Chem 23: 554-560, 1980.
8. Wall ME and Wani MC: Antineoplastic agents from plants. Annu Rev Pharmacol Toxicol 17: 117-132, 1977.
9. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R and Potmesil M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052-3055, 1991.
10. Natelson E, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N and Stehlin JS: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803: 224-230, 1996.
11. Burke TG: Chemistry of the camptothecins in the bloodstream: Drug stabilization and optimization of activity. Ann NY Acad Sci 803: 29-31, 1996.
12. Zhao H, Lee C, Sai P, Choe YH, Boro M, Pendri A, Duan S and Greenwald RB: 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J Org Chem 65: 4601-4606, 2000.
13. Burke TG and Mi Z: Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212: 285-287, 1993.
14. Burke TG and Mi Z: The structural basis of camptothecin interactions with human albumin: impact on drug stability. J Med Chem 37: 40-46, 1994.
15. Cao Z, Harris N, Kozielski A, Vardeman D and Giovanella B: Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem 41: 31-37, 1998.
16. Cao Z, Pantazis P, Mendoza J, Early J, Kozieslki A, Harris N, Vardeman D, Liehr J, Stehlin J and Giovanella B: Structure-activity relationship of alkyl camptothecin esters. Ann NY Acad Sci 992: 122-135, 2000.
17. Cao Z, Pantazis P, Mendoza J, Early J, Kozielski A, Harris N and Giovanella B: Structure-activity relationship of alkyl 9-nitrocamptothecin esters. Acta Pharmacol Sin 24: 109-119, 2003.
18. Kono A and Hara Y: Conversion of CPT-11 into SN-38 in human tissues. Jpn J Cancer Chemother 18: 2175-2178, 1991.
19. Kawato Y, Aonuma M, Matsumoto K and Sato K: Production of SN-38, a main metabolite of the camptothecin derivative CPT-11. Yakubutsu Dotai 6: 899-907, 1991.
20. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H and Nagai E: Metabolic activation of CPT-11. Biol Pharm Bull 17: 662-664, 1994.
21. Rivory LP, Bowles MR, Robert J and Pond SM: The conversion of irinotecan (CPT-11) to its active metabolite 7-ethyl-10-hydroxycamptothecin (SN38). Biochem Pharmacol 52: 1103-1111, 1996.
22. Mentlein R, Heiland S, and Heymann E: Simultaneous purification and comparative characterization of six serine hydrolases from rat liver microsomes. Arch Biochem Biophys 200: 547-559, 1980.
23. Mentlein R and Heymann E: Hydrolysis of ester- and amide-type drugs by the purified isoenzymes of nonspecific carboxyl-esterase from rat liver. Biochem Pharmacol 33: 1243-1248, 1984.
24. Neises B and Steglich W: Esterification of carboxylic acids with dicyclohexylcarbodiimide/4-dimethylaminopyridine:tert-butyl ethyl fumarate. Org Synth 63: 183-187, 1985.
25. Hassner A and Alexanian V: Direct room temperature esterification of carboxylic acids. Tetrahedron Lett 19: 4475-4478, 1978.
26. Ziegler FE and Berger GD: A mild method for the esterification of fatty acids. Synth Commun 9: 539-543, 1979.
27. Steglich W and Höfle G: N,N-dimethyl-4-pyridinamine, a very effective acylation catalyst. Angew Chem Int Ed Engl 8: 981, 1969.
28. Rao VB and Garzon-Aburbeh A: Water soluble prodrugs of camptothecin. US Patent: 4,943,579, 1990.
29. Wall ME and Wani MC: Water-soluble esters of camptothecin compounds: Non-toxic camptothecin prodrugs are prepared by esterifying the 20-position hydroxyl group of camptothecin derivatives. US Patent: 5,646,159, 1997.
30. Cao Z, Armstrong K, Shaw M, Petry E and Harris N: Nitration of camptothecin with various inorganic nitrate salts in concentrated sulfuric acid: a new preparation of anticancer drug 9-nitrocamptothecin. Synthesis pp1724-1730, 1998.